RFK Jr. pledged to fight Lyme disease. Does that include supporting a vaccine?

Pfizer and partner Valneva said they plan to file for regulatory approval of a Lyme vaccine that reduced Lyme cases by ~75% in trials with four doses delivered over two seasons but missed one statistical endpoint. The program faces meaningful regulatory and uptake headwinds given US precedent (GSK’s Lymerix was approved in 1998 then withdrawn in 2002 amid low demand and lawsuits with a ~$1M settlement) and current political risk from HHS Secretary RFK Jr.’s anti-vaccine positions, creating uncertainty for approval and adoption. Rising disease burden (an estimated ~476,000 US diagnoses/treated cases per year) driven by expanding tick ranges due to climate and land-use changes increases addressable demand, but public skepticism and the vaccine’s four-dose, ~75% efficacy profile may limit uptake.

Analysis

Pfizer/Valneva’s program is a classic binary-regulatory + reputation story: clinical readouts look “good enough” to file but not dominant, so the commercial outcome will be driven by regulatory messaging (FDA advisory panel and ACIP guidance) and payer willingness to reimburse a multi-dose, partial-efficacy product. Expect a two-stage roll: an approval-driven equity move at filing/approval, then a much slower, regionally patchy uptake driven by endemic geography, employer/occupational programs and state public-health campaigns.

Second-order winners are platform and distribution players that can convert partial efficacy into richer bundles — e.g., mRNA developers that can pivot to multivalent tickborne vaccines and specialty CROs/CMOs that scale seasonal two-year dosing; losers include incumbent large vaccine brands tied to childhood schedules if ACIP declines a routine recommendation. Litigation and political noise (GAO probes, politicized HHS) raise campaign-risk premium: even a clean safety profile could be met by tepid ACIP language that keeps the product out of VICP protection and insurer automatic coverage.

Time horizons: regulatory submission and advisory hearings are 3–12 months, ACIP and payer coverage 6–24 months, and measurable sales penetration (>10% uptake in endemic cohorts) 2–4 years. The most plausible reversal is a narrow safety signal or vocally influential political interference that converts adoption from “targeted prophylaxis” to effectively no commercial market — probability elevated compared with a typical vaccine approval because of the Lyme politics and litigation history.

Key Decisions for Investors

• Buy a tactical, size-constrained PFE call spread (12-month tenor, small notional 1–2% portfolio): if Pfizer secures approval and a targeted ACIP recommendation, expect a 6–12 month re-rating; downside limited to premium if advisory/ACIP disappoints.
• Add a higher-beta allocation to VALN (equity or 9–18 month calls, 0.5–1% portfolio): upside asymmetric if Valneva benefits from royalties/participation in US launch; trade is binary/volatility driven—cut on negative readouts or if Pfizer pivots away.
• Initiate a speculative long TARS position (small allocation or long-dated calls, target mid-stage readout early next year): successful proof that an oral acaricide works would materially change TAM dynamics and could reroute funding away from vaccines — potential 3x upside vs high clinical failure risk.
• Pair trade: small long MRNA exposure (12–24 month calls) vs short GSK (size limited): thesis is platform premium for next-gen multivalent tickborne vaccines; if mRNA shows clear pipeline progress, accelerates adoption and leaves legacy players under-allocated. Manage as a correlation trade with tight stops given sector idiosyncratic risks.